{"id":"meningococcal-b-bexsero","safety":{"commonSideEffects":[{"rate":"50-70","effect":"Injection site pain"},{"rate":"20-40","effect":"Injection site erythema"},{"rate":"20-40","effect":"Injection site swelling"},{"rate":"10-30","effect":"Fever"},{"rate":"20-40","effect":"Fatigue"},{"rate":"20-40","effect":"Myalgia"},{"rate":"20-40","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains recombinant meningococcal proteins (NadA, fHbp, NHBA, and PorA) that are recognized by the immune system as foreign antigens. Upon vaccination, B cells and T cells are activated to produce specific antibodies and cellular immunity against serogroup B meningococci, providing protection against invasive meningococcal disease caused by this serogroup.","oneSentence":"Bexsero is a recombinant protein vaccine that stimulates the immune system to produce antibodies against Neisseria meningitidis serogroup B surface antigens.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:54:28.284Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B in infants, children, adolescents, and adults"}]},"trialDetails":[{"nctId":"NCT04350138","phase":"PHASE2","title":"Safety and Efficacy Study of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) to Prevent Gonococcal Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-12-29","conditions":"Gonococcal Infection","enrollment":2606},{"nctId":"NCT05766904","phase":"PHASE3","title":"Efficacy Trial on Meningococcal B Vaccine for Preventing Gonorrhea Infections","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2023-05-04","conditions":"Gonorrhea, Sexually Transmitted Infection","enrollment":150},{"nctId":"NCT05294588","phase":"PHASE2","title":"Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2022-04-18","conditions":"Gonorrhea Male","enrollment":65},{"nctId":"NCT03621670","phase":"PHASE3","title":"Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-07-27","conditions":"Infections, Meningococcal","enrollment":1196},{"nctId":"NCT07395739","phase":"PHASE1","title":"A Phase I Clinical Trial to Assess the Safety and Immunogenicity of DX-104","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Yuguan Biotech Co., Ltd.（Delonix Bioworks)","startDate":"2026-02-24","conditions":"Neisseria Meningitidis Serogroup B","enrollment":30},{"nctId":"NCT06832514","phase":"PHASE4","title":"Investigating Gender and Sex Differences in Immune Responses Through Vaccination of Transgender and Cisgender Persons","status":"RECRUITING","sponsor":"University Ghent","startDate":"2025-01-31","conditions":"Meningococcal Meningitis, Serogroup B, Transgender Persons, Sex Differences in Immune Response","enrollment":250},{"nctId":"NCT06647407","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-11-05","conditions":"Meningococcal Immunization, Healthy Volunteers","enrollment":750},{"nctId":"NCT06128733","phase":"PHASE1, PHASE2","title":"Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-10-31","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":1215},{"nctId":"NCT07197762","phase":"PHASE4","title":"MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young Adults","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-11-04","conditions":"Neisseria Meningitidis","enrollment":125},{"nctId":"NCT07252804","phase":"PHASE4","title":"Immunogenicity and Safety of MenB Vaccine in Pediatric Patients With Autoimmune Rheumatic Diseases","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-01-01","conditions":"Autoimmune Rheumatologic Disease","enrollment":263},{"nctId":"NCT06995430","phase":"PHASE3","title":"A Phase 3 Study to Assess the Immune Response And Safety Of Rmenb+Omv Nz In Primed Healthy Participants (10 To 20 Years Old)","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-07-07","conditions":"Meningitis","enrollment":226},{"nctId":"NCT04166656","phase":"PHASE3","title":"Research Trial Assessing the Immunogenicity and Safety of Three Meningococcal B Vaccine Strategies Among Patients With Asplenia.","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-09-15","conditions":"Splenectomy","enrollment":84},{"nctId":"NCT04825223","phase":"PHASE1","title":"Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-03-29","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":576},{"nctId":"NCT04084769","phase":"PHASE3","title":"Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-09-03","conditions":"Meningococcal Immunisation (Healthy Volunteers)","enrollment":570},{"nctId":"NCT06113198","phase":"PHASE4","title":"A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants From 2 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2023-11-10","conditions":"Meningitis, Meningococcal","enrollment":50},{"nctId":"NCT06446752","phase":"PHASE3","title":"BIYELA - Bexsero Immunisation in Young Women in Africa","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2024-08-14","conditions":"Gonorrhea, Gonorrhea of Pharynx, Gonorrhea of Anus","enrollment":1100},{"nctId":"NCT04886154","phase":"PHASE1, PHASE2","title":"A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-06-14","conditions":"Infections, Meningococcal","enrollment":1440},{"nctId":"NCT05082285","phase":"PHASE2","title":"A Study on the Safety, Tolerability and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-11-29","conditions":"Infections, Meningococcal","enrollment":724},{"nctId":"NCT06033261","phase":"PHASE1, PHASE2","title":"A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-09-06","conditions":"Genital Herpes","enrollment":365},{"nctId":"NCT05873751","phase":"","title":"A Study to Learn About How Trumenba Vaccine Shots Work Against Gonorrhea Infection in Teenagers and Young Adults in the United States.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-04-24","conditions":"Gonorrhea, Chlamydia, Meningococcal Vaccines","enrollment":1307378},{"nctId":"NCT04415424","phase":"PHASE3","title":"Efficacy Study of 4CMenB (Bexsero®) to Prevent Gonorrhoea Infection in Gay and Bisexual Men","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kirby Institute","startDate":"2021-07-08","conditions":"Neisseria Gonorrheae Infection","enrollment":650},{"nctId":"NCT04318548","phase":"PHASE3","title":"Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2020-08-25","conditions":"Infections, Meningococcal","enrollment":945},{"nctId":"NCT02868970","phase":"PHASE4","title":"Pharmacists as Immunizers to Improve Coverage and Provider/Recipient Satisfaction","status":"COMPLETED","sponsor":"Canadian Immunization Research Network","startDate":"2017-02-15","conditions":"Healthy","enrollment":2404},{"nctId":"NCT06025487","phase":"PHASE2","title":"Meningococcal B Vaccine in Patients with Asplenia","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2024-03-12","conditions":"Splenectomy; Status","enrollment":80},{"nctId":"NCT04722003","phase":"PHASE2","title":"Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB Vaccination","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-11-01","conditions":"Gonorrhoea","enrollment":52},{"nctId":"NCT04893811","phase":"PHASE4","title":"Trial to Describe the Safety, Tolerability, and Immunogenicity of Trumenba When Administered to Immunocompromised Participants ≥10 Years of Age","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-08-18","conditions":"Meningococcal Vaccine","enrollment":53},{"nctId":"NCT04597424","phase":"PHASE3","title":"Combined Prevention of Sexually Transmitted Infections (STIs) in Men Who Have Sex With Men and Using Oral Tenofovir Disoproxil Fumarate/ Emtricitabine (TDF/FTC) for HIV Pre-Exposure Prophylaxis (PrEP)","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2021-01-19","conditions":"Unsafe Sex, Risk-Taking","enrollment":556},{"nctId":"NCT04707391","phase":"PHASE3","title":"Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-01-25","conditions":"Meningitis, Meningococcal","enrollment":1250},{"nctId":"NCT06314880","phase":"PHASE1","title":"Safety, Tolerability, and Immunogenicity of Recombinant Meningococcal Group B Vaccine (E.Coli)","status":"UNKNOWN","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2023-07-22","conditions":"Healthy Volunteers","enrollment":300},{"nctId":"NCT04645966","phase":"PHASE2","title":"A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants","status":"TERMINATED","sponsor":"Pfizer","startDate":"2020-11-26","conditions":"Meningococcal Vaccine","enrollment":326},{"nctId":"NCT04502693","phase":"PHASE3","title":"Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2020-08-14","conditions":"Infections, Meningococcal","enrollment":3657},{"nctId":"NCT04295733","phase":"","title":"Safety, Tolerability and Immunogenicity of 4CMenB Vaccine(2 Doses) in Adults With an Immunodeficiency","status":"COMPLETED","sponsor":"Ospedale Policlinico San Martino","startDate":"2020-02-06","conditions":"Acquired Immunodeficiency","enrollment":98},{"nctId":"NCT03632720","phase":"PHASE3","title":"Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-10","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":788},{"nctId":"NCT03135834","phase":"PHASE3","title":"A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-04-24","conditions":"Meningococcal Vaccine","enrollment":1610},{"nctId":"NCT03493919","phase":"PHASE4","title":"A Sourcing Study to Collect Human Blood Samples From Healthy Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-03-08","conditions":"Meningitis, Meningococcal","enrollment":1021},{"nctId":"NCT04440163","phase":"PHASE3","title":"MenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of Age","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-06-17","conditions":"Meningococcal Vaccine","enrollment":2431},{"nctId":"NCT04398849","phase":"","title":"Immunisation for Adolescents Against Serious Communicable Diseases (B Part of it NT)","status":"UNKNOWN","sponsor":"University of Adelaide","startDate":"2021-03-04","conditions":"Gonorrhea, Meningococcal Disease","enrollment":7100},{"nctId":"NCT03636906","phase":"PHASE1, PHASE2","title":"Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-04-08","conditions":"Respiratory Syncytial Virus Infections","enrollment":201},{"nctId":"NCT04297436","phase":"NA","title":"Gonococcal Vaccine Study in Key Populations in Kenya","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2021-05-31","conditions":"Gonorrhea","enrollment":50},{"nctId":"NCT05212935","phase":"","title":"A Surveillance Study on Timing and Coverage Of Rotavirus and MenB Vaccine Co-administration in Campania Region, Italy","status":"UNKNOWN","sponsor":"Federico II University","startDate":"2022-05","conditions":"Vaccination, Rotavirus Infections, Meningococcal Infections","enrollment":2000},{"nctId":"NCT04239430","phase":"","title":"Propositive (Protecting Positive People From Meningococcal Infection) Follow-up Study","status":"UNKNOWN","sponsor":"St George's, University of London","startDate":"2020-11-26","conditions":"HIV/AIDS, Meningococcal Disease","enrollment":55},{"nctId":"NCT01894919","phase":"PHASE3","title":"Antibody Persistence, and Safety and Tolerability of a Booster Dose of the Meningococcal B Vaccine After the Completion of the Vaccination Course in Study V72_28","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2013-06","conditions":"Meningoccocal Disease, Meningococcal Meningitis","enrollment":851},{"nctId":"NCT02398396","phase":"NA","title":"Investigating Meningococcal Vaccines in Adults","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-04","conditions":"Meningococcal Vaccines, Meningococcal Infections, Neisseria Meningitidis","enrollment":15},{"nctId":"NCT02482636","phase":"PHASE2","title":"Baby Vaccine Study (Sched3)","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-08","conditions":"Infectious Diseases","enrollment":189},{"nctId":"NCT04094883","phase":"PHASE4","title":"Study to Assess Gonorrhoeae Immune Responses Induced by a N. Meningitidis Vaccine","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2019-10-09","conditions":"Neisseria Gonorrhoeae Infection","enrollment":11},{"nctId":"NCT04875819","phase":"PHASE4","title":"Safety and Immunogenicity Following Meningococcal and Pneumococcal Immunization Among Adult People Living With HIV","status":"RECRUITING","sponsor":"Thomas Benfield","startDate":"2021-04-28","conditions":"Hiv, Meningococcal Infections, Pneumococcal Infections","enrollment":55},{"nctId":"NCT02569632","phase":"PHASE4","title":"Investigating the Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba)","status":"COMPLETED","sponsor":"UCSF Benioff Children's Hospital Oakland","startDate":"2015-01","conditions":"Meningococcal Infections","enrollment":18},{"nctId":"NCT03125616","phase":"PHASE4","title":"Babies Born Early Antibody Response to Men B Vaccination: BEAR Men B","status":"COMPLETED","sponsor":"St George's, University of London","startDate":"2017-08-01","conditions":"Prematurity, Vaccination, Meningococcal Disease","enrollment":136},{"nctId":"NCT03509051","phase":"NA","title":"Prospective Study on the Vaccine Response to Meningococcal B Vaccine After Allogeneic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-06-01","conditions":"Hematopoietic Stem Cell Transplant, Meningococcal Vaccine","enrollment":40},{"nctId":"NCT04515368","phase":"NA","title":"A Pilot Clinical Study of PET Scanning in Evaluation of Vaccine Reactogenicity","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2016-06-10","conditions":"Positron-Emission Tomography, Immunization Reaction","enrollment":54},{"nctId":"NCT02640677","phase":"","title":"Safety of 4CMenB Exposure During Pregnancy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-01-31","conditions":"Infections, Meningococcal","enrollment":2},{"nctId":"NCT02173704","phase":"PHASE3","title":"Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-09-11","conditions":"Meningococcal Disease, Infections, Meningococcal","enrollment":225},{"nctId":"NCT03587207","phase":"PHASE2","title":"Study to Assess Potential Immune Interference When GlaxoSmithKline (GSK) Biologicals' MenABCWY Vaccine is Administered to Healthy Subjects Aged 10-25 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-07-09","conditions":"Meningitis, Meningococcal","enrollment":520},{"nctId":"NCT02975596","phase":"NA","title":"MenB Vaccine: Implementation Via Information, Empowerment and Accessibility","status":"COMPLETED","sponsor":"University of Florida","startDate":"2016-12","conditions":"Meningococcal Vaccine","enrollment":1326},{"nctId":"NCT02946385","phase":"PHASE2","title":"Study to Assess the Immunological Long-term Persistence of Antibodies (Abs) 2 Years After GlaxoSmithKline (GSK) Meningococcal ABCWY Vaccination in the V102_15 (NCT02212457) and Response to a Booster in Adolescents","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-11-15","conditions":"Infections, Meningococcal","enrollment":604},{"nctId":"NCT02712177","phase":"","title":"Bexsero™and Routine Infant Vaccines: Effect of Coadministration on the Safety of Immunization","status":"COMPLETED","sponsor":"CHU de Quebec-Universite Laval","startDate":"2008-08","conditions":"Meningococcal Infections","enrollment":4535},{"nctId":"NCT03089086","phase":"PHASE4","title":"South Australian Meningococcal B Vaccine Herd Immunity Study","status":"COMPLETED","sponsor":"University of Adelaide","startDate":"2017-04-01","conditions":"Meningococcal Disease","enrollment":34489},{"nctId":"NCT02212457","phase":"PHASE2","title":"Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-08-21","conditions":"Infections, Meningococcal","enrollment":1063},{"nctId":"NCT03682939","phase":"PHASE4","title":"Evaluation of Safety and Immunogenicity of Meningococcal B and Meningococcal ACWY Vaccine in at Risk Population","status":"UNKNOWN","sponsor":"St George's, University of London","startDate":"2019-02-21","conditions":"Hiv, Meningitis, Meningococcal, HIV Infections","enrollment":55},{"nctId":"NCT00661713","phase":"PHASE2, PHASE3","title":"Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2008-06","conditions":"Meningococcal Disease","enrollment":1631},{"nctId":"NCT02583412","phase":"PHASE4","title":"Pilot Study of the Immunogenicity, Reactogenicity and Tolerability of Two Schedules of a 4CmenB Vaccine in Adolescents and Young Adults","status":"COMPLETED","sponsor":"Canadian Immunization Research Network","startDate":"2015-09","conditions":"Meningococcal Serogroup B","enrollment":120},{"nctId":"NCT02446743","phase":"PHASE3","title":"Combined Study - Phase 3b MenB Long Term Persistence in Adolescents","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-11-17","conditions":"Infections, Meningococcal","enrollment":531},{"nctId":"NCT02080559","phase":"PHASE4","title":"Investigating the Immune Response to 4CMenB in Infants","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2014-07-21","conditions":"Meningitis","enrollment":187},{"nctId":"NCT00962624","phase":"PHASE2","title":"Study of Meningococcal B Vaccine and ACWY Conjugate Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Prof. Elizabeth Miller","startDate":"2010-07","conditions":"Meningococcal Meningitis, Serogroup A, Meningococcal Meningitis, Serogroup B, Meningococcal Meningitis, Serogroup C","enrollment":38},{"nctId":"NCT00443157","phase":"PHASE2","title":"Meningococcal B Vaccination in University Students","status":"COMPLETED","sponsor":"Public Health England","startDate":"2006-02","conditions":"Neisseria Meningitidis Serogroup B","enrollment":50},{"nctId":"NCT00197795","phase":"PHASE2","title":"Immunogenicity and Reactogenicity of a Meningococcal B Outer Membrane Vesicle Vaccine Given in a 0,6,12 Month Schedule to Health UK Adults","status":"COMPLETED","sponsor":"Public Health England","startDate":"2005-01","conditions":"Neisseria Meningitidis","enrollment":30},{"nctId":"NCT02106390","phase":"PHASE3","title":"Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-06-05","conditions":"Infections, Meningococcal","enrollment":750},{"nctId":"NCT02491463","phase":"PHASE1","title":"A Study to Assess the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' RSV Investigational Vaccine (ChAd155-RSV) (GSK3389245A) in Healthy Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-07-23","conditions":"Respiratory Synctial Virus Infections","enrollment":73},{"nctId":"NCT00657709","phase":"PHASE3","title":"Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2008-03","conditions":"Serogroup B Meningococcal Meningitis","enrollment":3630},{"nctId":"NCT00944034","phase":"PHASE2, PHASE3","title":"Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2009-07","conditions":"Meningococcal Disease, Meningococcal Meningitis","enrollment":1588},{"nctId":"NCT01911221","phase":"PHASE3","title":"A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive.","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2013-08","conditions":"Prevention of the Meningococcal Disease","enrollment":13},{"nctId":"NCT02141516","phase":"PHASE3","title":"Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects.","status":"COMPLETED","sponsor":"Novartis","startDate":"2014-05","conditions":"Meningococcal Disease","enrollment":239},{"nctId":"NCT00297817","phase":"PHASE2","title":"Study of the Safety and Immune Response of Two Serogroup B Meningococcal Vaccines Administered to Healthy Adolescents","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2006-02","conditions":"Meningococcal Disease","enrollment":203},{"nctId":"NCT00774384","phase":"PHASE2","title":"Regulation of Mucosal Immune Response to Systemic MenB Vaccine","status":"COMPLETED","sponsor":"University Hospitals Bristol and Weston NHS Foundation Trust","startDate":"2009-09","conditions":"Meningococcal Infections","enrollment":9},{"nctId":"NCT00137917","phase":"PHASE2","title":"Immunogenicity & Safety Study of a Meningococcal Serogroup B Vaccine Given in a 3 Dose Schedule to Healthy Adolescents Aged 12-18 Yrs","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2002-07","conditions":"Infections, Meningococcal","enrollment":478},{"nctId":"NCT01339923","phase":"PHASE3","title":"A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2011-04","conditions":"Meningococcal Disease, Meningococcal Meningitis","enrollment":1409},{"nctId":"NCT01214850","phase":"PHASE3","title":"Novartis Vaccine and Diagnostics Carriage Trial","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-09","conditions":"N. Meningitidis Carriage","enrollment":2968},{"nctId":"NCT00560313","phase":"PHASE2","title":"Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-07","conditions":"Meningococcal Disease","enrollment":54},{"nctId":"NCT02305446","phase":"PHASE3","title":"Safety and Blood Donations in Adults Vaccinated With rMenB+OMV NZ.","status":"COMPLETED","sponsor":"Novartis","startDate":"2014-12","conditions":"Meningitis, Meningococcal, Serogroup B","enrollment":55},{"nctId":"NCT01973218","phase":"PHASE3","title":"Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years.","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2013-11","conditions":"Meningococcal Disease","enrollment":264},{"nctId":"NCT00381615","phase":"PHASE2","title":"Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2006-09","conditions":"Healthy","enrollment":147},{"nctId":"NCT00879814","phase":"PHASE1","title":"Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-04","conditions":"Meningitis, Meningococcal","enrollment":48},{"nctId":"NCT00808028","phase":"PHASE2","title":"A Study Evaluating Safety And Immunogenicity Of Meningococcal B Rlp2086 Vaccine In Adolescents","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-02","conditions":"Meningitis, Meningococcal","enrollment":538},{"nctId":"NCT01139021","phase":"PHASE3","title":"One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-06","conditions":"Meningococcal Disease","enrollment":508},{"nctId":"NCT00937521","phase":"PHASE2","title":"Safety and Immunogenicity in Dose-Ranging and Formulation-Finding Meningococcal B (MenB) Vaccine Study in 2-month-old Infants","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2009-07","conditions":"Meningococcal Meningitis, Meningococcal Infections","enrollment":1507},{"nctId":"NCT01478347","phase":"PHASE3","title":"A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk Adults","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2013-05","conditions":"Meningococcal Disease, Meningococcal Meningitis","enrollment":18},{"nctId":"NCT00721396","phase":"PHASE2","title":"Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2008-08","conditions":"Meningococcal Infections","enrollment":1885},{"nctId":"NCT00433914","phase":"PHASE2","title":"Safety, Tolerability and Immunogenicity of Two Different Formulations of Meningococcal B Recombinant Vaccine, When Administered to Healthy Infants","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-02","conditions":"Meningococcal Disease","enrollment":60},{"nctId":"NCT00847145","phase":"PHASE3","title":"Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2009-02","conditions":"Meningococcal Disease","enrollment":2249},{"nctId":"NCT01423084","phase":"PHASE3","title":"Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years","status":"COMPLETED","sponsor":"Novartis","startDate":"2011-08","conditions":"Meningococcal Disease, Meningococcal Meningitis","enrollment":344},{"nctId":"NCT01717638","phase":"PHASE3","title":"Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2012-11","conditions":"Meningococcal Disease, Meningococcal Meningitis","enrollment":805},{"nctId":"NCT00798304","phase":"PHASE2","title":"Study Evaluating Safety, Tolerability, and Immunogenicity of Meningococcal B Vaccine in Healthy Infants","status":"TERMINATED","sponsor":"Pfizer","startDate":"2009-01","conditions":"Meningitis, Meningococcal","enrollment":46},{"nctId":"NCT00780806","phase":"PHASE1, PHASE2","title":"Safety And Blood Collection Study Of Meningococcal B Rlp2086 Vaccine In Adults","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2008-10","conditions":"Meningitis, Meningococcal","enrollment":60},{"nctId":"NCT00297687","phase":"PHASE1","title":"Study Evaluating the Safety, Immunogenicity and Tolerability of Meningococcal Group B Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2006-03","conditions":"Meningitis, Meningococcal","enrollment":108}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MenB-4C"],"phase":"marketed","status":"active","brandName":"Meningococcal B (Bexsero)","genericName":"Meningococcal B (Bexsero)","companyName":"University of Sao Paulo General Hospital","companyId":"university-of-sao-paulo-general-hospital","modality":"Biologic","firstApprovalDate":"","aiSummary":"Bexsero, also known as the Meningococcal Group B Vaccine rMenB+OMV NZ, is a vaccine used to prevent Meningococcal Disease, specifically Meningitis caused by Serogroup B. It has been studied in clinical trials for its safety and efficacy in preventing Meningococcal Disease, as well as Gonococcal Infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}